ATLANTA, GA – – (Newsfile Corp. – November 11, 2020) – – Holzer & Holzer, LLC is investigating whether bluebird bio, Inc. (“bluebird” or the “Company”) (NASDAQ: BLUE) complied with federal securities laws. On November 4, 2020, the Company announced its submission to the FDA for approval of its bb1111 product will be delayed until late 2022. The price of bluebird’s stock fell following the announcement. If you purchased shares of bluebird and suffered a loss on that investment, you are encouraged to contact Marshall P. Dees, Esq. at email@example.com or Luke R. Kennedy, Esq. at firstname.lastname@example.org, or by toll-free telephone at (888) 508-6832 to discuss your legal rights.